t of the may be and the subject of the subject of the subject of the subject of the subject of the subject of the subject of th 三、关于部分募集资金投资项目新增实施主体的议案 公司本次部分募投项目新增实施主体,符合公司实际经营需要,有利于推动 募投项目的顺利实施,不属于募投项目的实质性变更以及变相改变募集资金用途 的情形,不存在损害公司及全体股东特别是中小股东利益的情形,不会对公司生 产经营造成重大不利影响,审议程序符合相关法律法规和公司《募集资金管理制 度》、《公司章程》等有关规定。我们同意公司本次部分募投项目变更实施主体 的事项。 一、关于使用暂时闲置募集资金进行现金管理的议案 上海微创电生理医疗科技股份有限公司独立董事 关于第三届董事会第四次会议相关议案的独立意见 在保障募集资金安全的前提下,公司使用暂时闲置募集资金(含超募资金) 进行现金管理,用于购买安全性高、流动性好的理财产品或存款类产品。董事会 审议该议案的表决程序合法、有效,符合《上市公司监管指引第2号一上市公司 募集 ...

证券代码：688351 证券简称：微电生理 2023 年第一季度报告 重要内容提示 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务信息 的真实、准确、完整。 一、 主要财务数据 2023 年第一季度报告 | --- | --- | --- | --- | --- | --- | |--------------------------------------------------------------------------------------------------------------------------|--------------|-------|-------|-------|-----------------------| | | | | | | | | | | | | | 单位：元 币种：人民币 | | 项目 | 本期金额 | | | 说明 | | | 非流动资产处置损益 | | | | | | | 越权审批，或无正式批准文件， 或偶发性的税收返还、减免 | | | | | | | 计入当期损益的政府补助，但与 公司正常经营业务密切相关，符 合国家政 ...

证券代码：688351 证券简称：微电生理 公告编号：2023-011 上海微创电生理医疗科技股份有限公司 关于召开 2022 年度暨 2023 年第一季度 业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： http://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 投资者可于 2023 年 04 月 19 日(星期三) 至 04 月 25 日(星期二)16:00 前登 录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 investors@everpace.com 进行提问。公司将在说明会上对投资者普遍关注的问 题进行回答。 上海微创电生理医疗科技股份有限公司（以下简称"公司"）已于 2023 年 3 月 29 日发布公司 2022 年度报告，并将于 2023 年 4 月 22 日发布公司 2023 年第 一季度报告，为便于广大投资者更全面深入地了解公司 2022 年度以及 2023 年第 一季度的经营成果、财务状况，公司计划于 2023 年 0 ...

Product Development and Innovation - The company received NMPA registration approval for two key products: the EasyStars™ disposable magnetic positioning catheter and the FireMagic® Cool 3D RF ablation catheter, breaking the import monopoly and filling a domestic gap in the atrial fibrillation treatment field[4]. - The company is advancing the development of the fourth-generation Columbus® 3D electrophysiological mapping system, which includes new features for automatic marking of ablation points and enhanced stability of pressure monitoring algorithms[4]. - The company has launched new products such as the OptimAblate® RF ablation system, designed for rapid arrhythmia ablation procedures, which integrates with the Columbus® system for real-time parameter sharing[9]. - The company is focusing on the development of high-precision catheters to enhance the accuracy and efficiency of treatment processes in electrophysiology[21]. - The company aims to enhance navigation precision and user experience through the integration of advanced technologies such as augmented reality in future product developments[85]. - The company has developed three core technology platforms in electrophysiology intervention and ablation treatment, focusing on image navigation, precision instruments, and energy therapy[170]. - The company has made breakthroughs in RF ablation and cryoablation technologies, improving product performance over imported counterparts[180]. - The company has integrated multi-channel temperature sensing technology, enhancing the safety of ablation procedures[180]. - The company has introduced a unique catheter product with dual magnetic sensors for precise positioning, enhancing surgical control[179]. - The company is committed to enhancing patient outcomes through the development of advanced medical technologies[164]. Financial Performance - The company achieved a revenue of 260 million yuan in 2022, representing a year-on-year growth of 36.99%[30]. - The net profit attributable to the parent company was 2.97 million yuan, marking a turnaround from loss to profit[30]. - The company's operating revenue for 2022 was ¥260,324,959.49, representing a 36.99% increase compared to ¥190,029,869.11 in 2021[45]. - The net profit attributable to shareholders for 2022 was ¥2,971,824.38, a significant recovery from a loss of ¥11,974,254.69 in 2021[45]. - The revenue after deducting non-core business income for 2022 was ¥257,519,752.42, up 35.96% from ¥189,410,755.10 in the previous year[45]. - The company reported a significant increase in revenue from equipment products, which surged by 265.60% to ¥41,670,815.94, although the gross margin decreased to 60.80%[148]. - The gross margin for medical devices was 69.71%, a decrease of 2.84 percentage points compared to the previous year[148]. - The company reported a total revenue of ¥161,069,000, with a net profit of ¥109,016,363.46, indicating a strong performance in the current period[191]. Market Presence and Sales Strategy - The company’s products are sold in over 700 terminal hospitals across 31 provinces in China and exported to 30 countries including France, Italy, and Spain[10]. - The company is positioned as one of the few manufacturers globally to provide a complete solution for three-dimensional cardiac electrophysiology devices and consumables[19]. - The company employs a sales model that combines equipment sales, deployment, and clinical support services to enhance market penetration[82]. - The company plans to expand its marketing network to increase market share and product penetration, leveraging existing customer resources[130]. - The company is focused on increasing its market share in the domestic market through new product launches and enhancing brand influence in the electrophysiology industry[137]. - The company aims to enhance its global sales network and brand recognition, striving to become an international medical device enterprise rooted in China[135]. Research and Development - The company has applied for 102 new patents globally, with 41 patents granted during the reporting period, enhancing its global patent portfolio[4]. - The company has achieved a total R&D investment of ¥95,717,561.34, representing a 6.27% increase compared to the previous year[187]. - The company has cumulatively invested ¥46,786,530.02 in the cryoablation catheter project, which is also awaiting NMPA registration in 2023[195]. - The company has reported a significant increase in R&D personnel compensation, totaling ¥5,228.23 million, compared to ¥4,335.39 million in the previous period[198]. - The company has developed a rapid 3D modeling algorithm for cardiac mapping, significantly reducing modeling time and improving intraoperative navigation[179]. Strategic Collaborations and Market Expansion - The company has established strategic collaborations for technology deployment in potential application areas, including partnerships for the development of magnetic navigation modules for the 3D mapping system[4]. - The company plans to deepen its focus on electrophysiology while expanding its product line and developing a comprehensive medical solution[135]. - The company plans to accelerate international expansion and strengthen group construction in response to new market opportunities and challenges[130]. - The company is committed to smart manufacturing to reduce production costs and improve efficiency in response to rising labor costs and management expenses[137]. Operational Risks and Governance - The management has outlined various operational risks and corresponding mitigation strategies in the report[36]. - The management emphasizes the importance of investor awareness regarding potential risks associated with forward-looking statements in the report[37]. - The company is enhancing its governance structure to ensure compliance with relevant laws and regulations, promoting efficient and stable operations[138].

2022 年第三季度报告 单位：元 币种：人民币 1 / 14 证券代码：688351 证券简称：微电生理 上海微创电生理医疗科技股份有限公司 2022 年第三季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务 信息的真实、准确、完整。 第三季度财务报表是否经审计 □是 √否 一、 主要财务数据 主要会计数据和财务指标 本报告期比 | --- | --- | --- | --- | --- | |------------------------------------------------|---------------|---------------------------|----------------|------------------------------- ...